A population pharmacokinetic model for low-dose methotrexate and its polyglutamated metabolites in red blood cells

Clinical Pharmacokinetics

Volumn 52, Issue 6, 2013, Pages 475-485

  Korell, Julia ^a   Stamp, Lisa K ^b   Barclay, Murray L ^b,c   Dalrymple, Judith M ^c   Drake, Jill ^b   Zhang, Mei ^b   Duffull, Stephen B ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

ARTICLE; BODY SURFACE; BODY WEIGHT; CLINICAL ARTICLE; COMPARTMENT MODEL; DRUG CLEARANCE; DRUG DISTRIBUTION; ERYTHROCYTE METABOLISM; GLOMERULUS FILTRATION RATE; HUMAN; LOW DRUG DOSE; MEAN CORPUSCULAR VOLUME; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTES; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; MODELS, BIOLOGICAL; POLYGLUTAMIC ACID;

EID: 84878700322     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0052-y     Document Type: Article

References (23)

1. Morgan C, Lunt M, Brightwell H, et al. Contribution of patient related differences to multidrug resistance in rheumatoid arthritis. Ann Rheum Dis. 2003;62(1):15-9.
2. Angelis-Stoforidis P, Vajda F, Christophidis N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheumatol. 1999;17(3):313-20.
3. Dervieux T, Furst D, Lein D, et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 2004;50(9):2766-74.
4. Volk EL, Schneider E. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003;63(17):5538-43.
5. Zeng H, Chen Z, Belinsky M, et al. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1. Cancer Res. 2001;61(19):7225-32.
6. Allegra C, Chabner B, Drake J, et al. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem. 1985;260(17):9720-6.
7. Chabner B, Allegra C, Curt G, et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Investig. 1985;76(3):907-12.
8. Dervieux T, Furst D, Lein D, et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentered cross sectional observational study. Ann Rheum Dis. 2005;64(8):1180-5.
9. Stamp L, O'Donnell J, Chapman P, et al. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis Rheum. 2010;62(2):359-68.
10. Dalrymple J, Stamp L, O'Donnell J, et al. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2008;58(11):3299-308.
11. Stamp L, Barclay M, O'Donnell J, et al. Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. J Rheumatol. 2011;38(12):2540-7.
12. Beal S. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28(5):481-504.
13. Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004;31(4):645-8.
14. Herman R, Veng Pedersen P, Hoffman J, et al. Pharmacokinetics of low dose methotrexate in rheumatoid arthritis patients. J Pharm Sci. 1989;78(2):165-71.
15. Rhee M, Lindau-Shepard B, Chave K, et al. Characterization of human cellular gamma-glutamyl hydrolase. Mol Pharmacol. 1998;53(6):1040-6.
16. Janmahasatian S, Duffull S, Ash S, et al. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051-65.
17. Hardman J, Limbird L, editors. Goodman and Gilman's: the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill; 2001.
18. Bergstrand M, Hooker A, Wallin J, et al. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143-51.
19. Morrison P, Allegra C. The kinetics of methotrexate polyglutamation in human breast cancer cells. Arch Biochem Biophys. 1987;254(2):597-610.
20. Holford N. A size standard for pharmacokinetics. Clin Pharmacokinet. 1996;30(5):329-32.
21. Stamp L, O'Donnell J, Chapman P, et al. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long term methotrexate treatment. Arthritis Rheum. 2009;60(8):2248-56.
22. Savic R, Karlsson M. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11(3):558-69.
23. Sirotnak F, Tolner B. Carrier-mediated membrane transport of folates in mammalian cells. Annu Rev Nutr. 1999;19(1):91-122.